New high-capacity multi-omics platform attracts MRFF Critical Infrastructure funding

Australian BioCommons is part of a powerful new collaboration to build critical national research infrastructure that addresses unmet needs through new discovery and diagnostic capability in multi-omics. $15.83M of combined funding will support creation of the OMIX3 Platform, which will deliver integrated proteomics, lipidomics and metabolomics analysis of biological samples. 

Significant co-investment from partners including Bioplatforms Australia, Thermo Fisher Scientific and the University of Melbourne was complemented with funding from the Australian Government’s Medical Research Future Fund’s Critical Research Infrastructure initiative. The development of this world-leading multi-omics platform will expand existing NCRIS-funded infrastructure and leverage an outstanding collaborative network of researchers, clinicians and commercial partners.

The OMIX3 Platform will be an integrated high-throughput, multi-omics facility for processing clinical samples, from point of collection and biobanking, through to comprehensive, proteomic, metabolomic and lipidomic analysis on parallel mass spectrometry platforms. Australian BioCommons’ Human Genome Informatics team will contribute their extensive experience in developing sensitive data storage, sharing and analytics capabilities.

Led by the University of Melbourne’s Professor Olivia Carter, the OMIX3: High-capacity integrated multi-omics project includes partners and collaborators from Melbourne School of Psychological Sciences, Murdoch Children’s Research Institute, Melbourne School of Biomedical Sciences, Melbourne Dental School, Thermo Fisher Scientific, Australian BioCommons and Bioplatforms Australia.

You can learn more about the project by reading these announcements from other partners:

Christina Hall2024